Retreatment of hepatitis C patients with pegylated interferon combined with ribavirin in non-responders to interferon plus ribavirin. Is it different in real life?
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2334
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Retreatment of hepatitis C patients with pegylated interferon combined with ribavirin in non-responders to interferon plus ribavirin. Is it different in real life? ; volume:10 ; number:1 ; day:20 ; month:7 ; year:2010 ; pages:1-7 ; date:12.2010
BMC infectious diseases ; 10, Heft 1 (20.7.2010), 1-7, 12.2010
- Creator
-
Goncales, Fernando L.
- Contributor
-
Moma, Camila A.
Vigani, Aline G.
Angerami, Adriana FCF
Gonçales, Eduardo SL
Tozzo, Raquel
Pavan, Maria HP
Goncales, Neiva SL
SpringerLink (Online service)
- DOI
-
10.1186/1471-2334-10-212
- URN
-
urn:nbn:de:1111-2016030258913
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:38 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Goncales, Fernando L.
- Moma, Camila A.
- Vigani, Aline G.
- Angerami, Adriana FCF
- Gonçales, Eduardo SL
- Tozzo, Raquel
- Pavan, Maria HP
- Goncales, Neiva SL
- SpringerLink (Online service)
Other Objects (12)
Pegylated Interferon and Ribavirin Dosing Strategies to Enhance Sustained Virologic Response
Effects of Host and virus related factors on Interferon-α+ribavirin and Pegylated-interferon+ribavirin treatment outcomes in Chronic Hepatitis C patients
Hepatitis C virus core protein substitutions affect the response to pegylated-interferon and ribavirin therapy
Retreatment of hepatitis C non-responsive to Interferon. A placebo controlled randomized trial of Ribavirin monotherapy versus combination therapy with Ribavirin and Interferon in 121 patients in the Benelux [ISRCTN53821378]
Improvement in quality of life measures in patients with refractory hepatitis C, responding to re-treatment with Pegylated interferon alpha -2b and ribavirin
How hepatitis C patients manage the treatment process of pegylated interferon and ribavirin therapy: a qualitative study
Oxidative status and the response to pegylated-interferon alpha2A plus ribavirin in chronic genotype 4 HCV hepatitis
Occult hepatitis B infection in egyptian chronic hepatitis C patients: prevalence, impact on pegylated interferon/ribavirin therapy
Pegylated interferon may be considered in chronic viral hepatitis E resistant to ribavirin in kidney transplant recipients
Job performance in chronic hepatitis C virus patients treated with pegylated interferon-α2b plus ribavirin: an observational study
Monotherapie mit Interferon alpha und Kombinationstherapie mit Interferon alpha und Ribavirin bei chronischer Hepatitis-C-Infektion
Heterogeneity of hepatitis C virus in genotype 1 patients treated with the combination therapy of pegylated interferon and ribavirin
Pegylated Interferon and Ribavirin Dosing Strategies to Enhance Sustained Virologic Response
Effects of Host and virus related factors on Interferon-α+ribavirin and Pegylated-interferon+ribavirin treatment outcomes in Chronic Hepatitis C patients
Hepatitis C virus core protein substitutions affect the response to pegylated-interferon and ribavirin therapy
Retreatment of hepatitis C non-responsive to Interferon. A placebo controlled randomized trial of Ribavirin monotherapy versus combination therapy with Ribavirin and Interferon in 121 patients in the Benelux [ISRCTN53821378]
Improvement in quality of life measures in patients with refractory hepatitis C, responding to re-treatment with Pegylated interferon alpha -2b and ribavirin
How hepatitis C patients manage the treatment process of pegylated interferon and ribavirin therapy: a qualitative study
Oxidative status and the response to pegylated-interferon alpha2A plus ribavirin in chronic genotype 4 HCV hepatitis
Occult hepatitis B infection in egyptian chronic hepatitis C patients: prevalence, impact on pegylated interferon/ribavirin therapy
Pegylated interferon may be considered in chronic viral hepatitis E resistant to ribavirin in kidney transplant recipients
Job performance in chronic hepatitis C virus patients treated with pegylated interferon-α2b plus ribavirin: an observational study
Monotherapie mit Interferon alpha und Kombinationstherapie mit Interferon alpha und Ribavirin bei chronischer Hepatitis-C-Infektion
Heterogeneity of hepatitis C virus in genotype 1 patients treated with the combination therapy of pegylated interferon and ribavirin
Pegylated Interferon and Ribavirin Dosing Strategies to Enhance Sustained Virologic Response
Effects of Host and virus related factors on Interferon-α+ribavirin and Pegylated-interferon+ribavirin treatment outcomes in Chronic Hepatitis C patients
Hepatitis C virus core protein substitutions affect the response to pegylated-interferon and ribavirin therapy
Retreatment of hepatitis C non-responsive to Interferon. A placebo controlled randomized trial of Ribavirin monotherapy versus combination therapy with Ribavirin and Interferon in 121 patients in the Benelux [ISRCTN53821378]
Improvement in quality of life measures in patients with refractory hepatitis C, responding to re-treatment with Pegylated interferon alpha -2b and ribavirin
How hepatitis C patients manage the treatment process of pegylated interferon and ribavirin therapy: a qualitative study
Oxidative status and the response to pegylated-interferon alpha2A plus ribavirin in chronic genotype 4 HCV hepatitis
Occult hepatitis B infection in egyptian chronic hepatitis C patients: prevalence, impact on pegylated interferon/ribavirin therapy
Pegylated interferon may be considered in chronic viral hepatitis E resistant to ribavirin in kidney transplant recipients
Job performance in chronic hepatitis C virus patients treated with pegylated interferon-α2b plus ribavirin: an observational study
Monotherapie mit Interferon alpha und Kombinationstherapie mit Interferon alpha und Ribavirin bei chronischer Hepatitis-C-Infektion